Berlin - Delayed Quote • EUR Beyond Air Inc (48L.BE) Follow 1.0900 -0.0100 (-0.91%) At close: 8:30 PM GMT+2 Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw Table View List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Date Close Open High Low Volume O H L C Vol AAPL Loading Chart for 48L.BE 1D 5D 1M 3M 6M YTD 1Y 2Y 5Y All Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Recent News: 48L.BE View More All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Beyond Air® Announces Pricing of $16.0 Million Registered Direct Offering of Common Stock and Warrants Beyond Air® Reports Financial Results for Third Quarter of Fiscal Year 2024 Beyond Air® Schedules Third Fiscal Quarter 2024 Financial Results Conference Call and Webcast Beyond Cancer™ Phase 1 Study Clears Cohort 1 in Patients with Advanced Relapsed or Refractory Unresectable Primary or Metastatic Cutaneous or Subcutaneous Solid Tumors Beyond Air Independent Director Acquires 102% More Stock Insider Buying: CEO Steven Lisi Acquires 77,775 Shares of Beyond Air Inc Beyond Air® To Participate in the 35th Annual Piper Sandler Healthcare Conference Beyond Air® Reports Financial Results for Second Quarter of Fiscal Year 2024 Beyond Cancer™ Presents Positive First-in-Human Clinical Data for Ultra-High Concentration Nitric Oxide (UNO) Therapy in Solid Tumors During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting Beyond Air® Schedules Second Fiscal Quarter 2024 Financial Results Conference Call and Webcast Beyond Air® To Participate in the Truist Securities BioPharma Symposium Beyond Cancer™ Publishes Pre-Clinical Data in Cells Demonstrating that the Combination of Ultra-High Concentration Nitric Oxide (UNO) and Anti-mPD-1 Therapy Improves Tumor Regression Rates and Survival in Mice
